These are the monthly highlights of our progress.
American Association of Equine Practitioners Conference
We had a booth at the 68th Annual Convention of the American Association of Equine Practitioners, AAEP, in San Antonio, Texas. This is the largest equine conference of the year, with 4200 people registered (1400 exhibitors, 2800 DVMs, Guests, Students, and Techs). This and our recent ad in The Horse magazine were excellent vehicles to introduce the equine community to IsoPet® therapy. We obtained new contacts considering becoming an equine therapy IsoPet® regional center. This will require significant follow-up effort.
John Heindrcih, PhD, DVM attended and provided important insights. He recently retired as the owner of the Ventana Animal Hospital in Albuquerque, NM, and is our new veterinarian consultant.
Johns Hopkins VX-2/Rabbit Study
We translated our animal test plan into the FDA GLP protocol. It is now divided into Phase 1 to determine biokinetics and Phase 2 to measure effectiveness.
Johns Hopkins obtained the IACUC approval to initiate Phase 1 and is preparing an amendment to include the control group of rabbits for Phase 2.
(Mike Korenko, Sc.D • CEO • President – December 1, 2022)
Quality Management System
We are continually strengthening our Quality Management System. This month we audited IsoTherapeutics, our current IsoPet® particle manufacturing center. We also completed the sterilization validation runs on our particles, which is necessary for the FDA IDE.
Intellectual Property
Protecting our intellectual property is always a priority. We are working on two new patents, but I can only publicly disclose the content after
they are filed.
Mike Korenko, Sc. D
CEO & President Vivos, Inc.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
Home Page Cover Image:
Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.
Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y) phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® Therapy Application(s)
Precision Radionuclide Therapy (PRnT)
Vivos Inc. - (OTCQB: RDGL) Investor Relations
Contact
| bg-primary | |
| bg-primary-light | |
| bg-primary-dark | |
| bg-secondary | |
| bg-secondary-dark |
| body | |
| top-header | |
| header | |
| content |
| background | |
| text color | |
| link color | |
| horizontal line |
| style 1 | |
| style 2 | |
| style 3 |
| social icons | |
| navigation color | |
| subnav background |
| background color | |
| navigation color |
Note: All changes made here will be applied to your entire website.
Write a comment
Warren Wicher (Wednesday, 14 December 2022 19:46)
I came across a perplexing story about Duke University developing a “gel therapy” using Iodine 131.
It was disturbing as it seemed to intrude on Radiogel/Isopet technology,
https://scitechdaily.com/most-effective-treatment-yet-new-radioactive-tumor-implant-obliterates-pancreatic-cancer/
Should there be concern about “David vs. Goliath regarding Big Pharma displacing micro cap companies?
Just a concerned advocate.